相关实验视频

Updated: Jan 11, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.5K

免疫检查点抑制剂相关结肠炎中的C-反应性蛋白:证据和知识差距的范围审查

Ryuichi Ohta1,2,3, Yoshinori Ryu1,3, Kaoru Tanaka2

  • 1Department of Community Care, Unnan City Hospital, Unnan, Shimane, Japan.

Cancer management and research
|November 13, 2025
PubMed

Insights

在癌症患者中,C-反应蛋白 (CRP) 对于诊断免疫介导腹和结肠炎 (IMDC) 的证据有限. 虽然CRP具有潜在的支持性,但缺乏验证的值,不能取代IMDC的当前诊断方法.

科学领域:

  • 在瘤学瘤学.
  • 胃肠病学 胃肠病学
  • 免疫学 免疫学 免疫学

背景情况:

  • 免疫检查点抑制剂 (ICI) 是关键的癌症疗法,但可以引起免疫媒介腹和结肠炎 (IMDC).
  • 准确的IMDC诊断和严重程度评估至关重要,但往往需要侵入性手术.
  • C-反应蛋白 (CRP) 是潜在的炎症生物标志物,但其在IMDC中的作用尚不清楚.

研究的目的:

  • 进行范围审查,对C反应蛋白 (CRP) 和免疫介导腹和结肠炎 (IMDC) 的证据进行映射.
  • 识别有关CRP在诊断和评估IMDC严重性的有用性方面的知识差距.

主要方法:

  • 在PubMed,Embase和Web of Science (2010年1月至2025年4月) 进行了全面的文献搜索.
  • 包括的研究集中在接受ICI的成年患者中,有胃肠道免疫相关的不良事件和报告的CRP水平.
  • 数据提取涉及研究设计,患者特征,CRP测量以及与IMDC诊断,严重程度或结果的关联.

主要成果:

  • 包括5个观察性研究,包括583名患者.
  • 只有一个研究分析了确认IMDC的CRP,显示了与严重程度的相关性,但没有验证的诊断值.
  • 没有研究提供了足够的数据关于CRP的IMDC诊断准确性 (灵敏度,特异性,预测值).

结论:

  • 将CRP与IMDC联系在一起的证据有限且异质,没有经过验证的诊断性能数据.
  • 虽然CRP可以作为进一步调查的辅助标记,但它不能取代已建立的IMDC诊断途径.
  • 未来的研究应该专注于前性研究,将CRP与器官特异性生物标志物相结合,用于IMDC分拣和严重性评估.
抽象的

No abstract available in PubMed .

关键词:
在C-反应性蛋白质中.生物标志物 生物标志物大肠炎是一种大肠炎.免疫检查点抑制剂 免疫检查点抑制剂与免疫相关的不良事件.范围审查 范围审查审查

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.6K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
459
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
939
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473